Category: Press Releases

Drug Delivery, Press Releases

XPhyto reports excellent Rotigotine in-vitro/ex-vivo results for Parkinson’s disease treatment

Oct 18, 2022

Vancouver, Canada, and Uttenweiler, Germany (October 18, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Drug Delivery, Press Releases

XPhyto completes Rotigotine transdermal patch optimization and comparative skin absorption study

Oct 11, 2022

Vancouver, Canada, and Uttenweiler, Germany (October 11, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Diagnostics, Press Releases

XPhyto Signs Letter of Intent for US Manufacturing and Strategic Business Opportunities

Oct 5, 2022

Vancouver, Canada, and Uttenweiler, Germany (October 4, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Press Releases, Psychedelics

XPhyto Files Patent Application for Library of Novel Psychedelic Compounds

Sep 20, 2022

Vancouver, Canada, and Uttenweiler, Germany (September 20, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Diagnostics, Press Releases

XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease

Jul 18, 2022

Vancouver, Canada, and Uttenweiler, Germany (July 18, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Press Releases

Prof. Dr. Raimar Loebenberg receives Leadership Award from the Canadian Society for Pharmaceutical Sciences

Jun 27, 2022

Vancouver, Canada, and Uttenweiler, Germany (June 27, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to congratulate...

Continue Reading

Drug Delivery, Press Releases

XPhyto adds pharmaceutical manufacturing expert Dr. Florian A. Sahr to its European team

Jun 8, 2022

Vancouver, Canada, and Uttenweiler, Germany (June 8, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Drug Delivery, Press Releases

XPhyto reports product developments on platform-based Rotigotine transdermal patch for Parkinson’s disease

May 9, 2022

Vancouver, Canada, and Uttenweiler, Germany (May 9, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Diagnostics, Press Releases

XPhyto, Biosensors market and product developments on platform-based oral dissolvable biosensors for oral health and infectious disease

Apr 12, 2022

Vancouver, Canada, and Uttenweiler, Germany (April 11, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Drug Delivery, Press Releases

XPhyto reports market and product developments on platform-based Rotigotine transdermal patch for Parkinson’s disease

Apr 4, 2022

Vancouver, Canada, and Uttenweiler, Germany (April 4, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Press Releases, Psychedelics

XPhyto provides progress update on Psychedelic Medicine Programs and Novel Compounds Milestone

Feb 22, 2022

Vancouver, Canada, and Uttenweiler, Germany (February 22, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Press Releases

XPhyto Reports on its Three Primary Business Divisions

Feb 8, 2022

Vancouver, Canada, and Uttenweiler, Germany (February 8, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading